Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

Literature DB >> 35633498

Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

L Bartalena¹, C Marcocci², M L Tanda³, M Marinò².

Abstract

Entities: Chemical

Keywords: Graves’ orbitopathy; Hearing loss; Teprotumumab; Thyroid-eye disease

Mesh：

Substances：

Year: 2022 PMID： 35633498 DOI： 10.1007/s40618-022-01829-z

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 5.467

× No keyword cloud information.

5 in total

1. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.

Authors: Raymond S Douglas; George J Kahaly; Shoaib Ugradar; Heike Elflein; Katharina A Ponto; Brian T Fowler; Roger Dailey; Gerald J Harris; Jade Schiffman; Rosa Tang; Sara Wester; Amy Patel Jain; Claudio Marcocci; Michele Marinò; Alessandro Antonelli; Anja Eckstein; Dagmar Führer-Sakel; Mario Salvi; Saba Sile; Megan Francis-Sedlak; Robert J Holt; Terry J Smith
Journal: Ophthalmology Date: 2021-10-21 Impact factor: 12.079

2. Letter to the editor regarding Bartalena et al. 2022.

Authors: T J Smith
Journal: J Endocrinol Invest Date: 2022-06-01 Impact factor: 5.467

3. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

Authors: L Bartalena; C Marcocci; M L Tanda; M Marinò
Journal: J Endocrinol Invest Date: 2022-05-28 Impact factor: 5.467

4. Teprotumumab for the Treatment of Active Thyroid Eye Disease.

Authors: Raymond S Douglas; George J Kahaly; Amy Patel; Saba Sile; Elizabeth H Z Thompson; Renee Perdok; James C Fleming; Brian T Fowler; Claudio Marcocci; Michele Marinò; Alessandro Antonelli; Roger Dailey; Gerald J Harris; Anja Eckstein; Jade Schiffman; Rosa Tang; Christine Nelson; Mario Salvi; Sara Wester; Jeffrey W Sherman; Thomas Vescio; Robert J Holt; Terry J Smith
Journal: N Engl J Med Date: 2020-01-23 Impact factor: 91.245

5. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.

Authors: Raymond S Douglas; Roger Dailey; Prem S Subramanian; Giuseppe Barbesino; Shoaib Ugradar; Ryan Batten; Rana A Qadeer; Chris Cameron
Journal: JAMA Ophthalmol Date: 2022-04-01 Impact factor: 7.389

5 in total

3 in total

Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

1. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.

2. Letter to the editor regarding Bartalena et al. 2022.

3. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

4. Teprotumumab for the Treatment of Active Thyroid Eye Disease.

5. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.

1. Letter to the editor regarding Bartalena et al. 2022.

2. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

3. SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review.